ALKS: Alkermes plc Stock

by  •  • Comments Off on ALKS: Alkermes plc Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 4,151.78
Enterprise Value ($M) 3,634.04
Book Value ($M) 1,254.76
Book Value / Share 7.42
Price / Book 3.31
NCAV ($M) 565.68
NCAV / Share 3.34
Price / NCAV 7.34

Profitability (mra)
Return on Invested Capital (ROIC) 0.27
Return on Assets (ROA) 0.23
Return on Equity (ROE) 0.43

Liquidity (mrq)
Quick Ratio 2.69
Current Ratio 3.13

Balance Sheet (mrq) ($M)
Current Assets 1,434.82
Assets 2,123.90
Liabilities 869.13
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 1,663.40
Operating Income 414.12
Net Income 355.76
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 401.35
Cash from Investing 53.36
Cash from Financing -289.71

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A Vanguard Group Inc 12.56 13.03
02-08 13G Wellington Management Group Llp 9.13 152.16
01-24 13G State Street Corp 5.60
01-08 13G/A BlackRock Inc. 18.00 81.94
08-24 13D/A Sarissa Capital Management LP 5.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q
2024-02-21 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K
2023-10-25 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q
2023-07-26 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-01 405,343 2,344,736 17.29
2024-04-30 313,636 2,168,589 14.46
2024-04-29 457,735 632,838 72.33
2024-04-26 132,446 464,910 28.49

(click for more detail)

Similar Companies
AGIO – Agios Pharmaceuticals, Inc. AKRO – Akero Therapeutics, Inc.
ALEC – Alector, Inc. ALLK – Allakos Inc.
ALLO – Allogene Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io